PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Lead Pharma and Roche enter €260m collaboration agreement

Dutch company Lead Pharma has entered a collaboration and licence agreement with Swiss pharma giant Roche to develop oral small molecules for a ‘broad range’ of immune mediated diseases.

Lead Pharma and Roche are set to collaborate on research activities up to the selection of a pre-clinical candidate, after which Roche is set to assume responsibility for further development and global commercialisation.

“We are committed to advancing innovative science and transformative medicines for people affected by different immune mediated diseases,” said James Sabry, global head, Roche Pharma Partnering.

“We are looking forward to further building on our expertise in this field and collaborating with Lead Pharma, aiming to make a difference for those patients,” he added.

As part of the agreement, Lead Pharma will receive an upfront payment of €10m and will be eligible to receive research funding and pre-clinical payments. In total, potential payments – including research, development, regulatory and sales milestones – could reach €260m plus royalties on worldwide sales.

“This is the second project we partner with one of the largest pharmaceutical companies under our Discover, Design and Deliver platform,” said Arthur Oubrie, chief scientific officer of Lead Pharma.

“Our rigorous target selection process, translational screening cascade, and smart medicinal chemistry have been essential to bring this project to this stage. We are keen to collaborate with our colleagues at Roche to bring this novel approach to patients,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026